SCHEMBL3023232

SCHEMBL3023232

CCN(CC)c1ccc(Nc2ccnc(Cl)n2)c(C)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 5/20 0.42
CYP2C19 P33261 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42
PSEN1 P49768 1/20 0.41
PSEN2 P49810 1/20 0.41
APH1B Q8WW43 1/20 0.41
NCSTN Q92542 1/20 0.41
APH1A Q96BI3 1/20 0.41
PSENEN Q9NZ42 1/20 0.41
MAPT P10636 8/20 0.41
GHSR Q92847 1/20 0.41
HTT P42858 2/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
S100B P04271 1/20 0.40
RPS6KA2 Q15349 1/20 0.39
POLB P06746 2/20 0.39
LMNA P02545 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3030575 0.82 MAPK14 (0.37) CYP2C19MEN1KMT2ACYP1A2
SCHEMBL6978712 0.80 MEN1 (0.58) CYP2C19NPSR1MAPTHTTMEN1
SCHEMBL17260953 0.77 TNIK (0.43) CYP2C19MAPTCYP1A2
SCHEMBL8144017 0.76 HSP90AA1 (0.49)
SCHEMBL8141002 0.75 PSEN1 (0.41) GFERCYP2C19NPSR1PSEN1PSEN2
SCHEMBL15489512 0.73 MAPK10 (0.57) HTT
SCHEMBL8141252 0.72 CCNE1 (0.47) NPSR1PSEN1PSEN2APH1BNCSTN
SCHEMBL3914779 0.71 S100B (0.55) GFERCYP2C19NPSR1MAPTGHSR
SCHEMBL5388892 0.71 MAPK14 (0.46) MEN1KMT2AALDH1A1NPC1RAB9A
SCHEMBL11421724 0.69 RPS6KA2 (0.52) GFERCYP2C19NPSR1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100204230-A1 PIPERAZINE DERIVATIVES FOR TREATMENT OF AD AND RELATED CONDITIONS MERCK SHARP & DOHME CORP. 2010-08-12 US disclosed
US-20100204230-A1 PIPERAZINE DERIVATIVES FOR TREATMENT OF AD AND RELATED CONDITIONS MERCK SHARP & DOHME CORP. 2010-08-12 US disclosed
US-20100204230-A1 PIPERAZINE DERIVATIVES FOR TREATMENT OF AD AND RELATED CONDITIONS MERCK SHARP & DOHME CORP. 2010-08-12 US disclosed
WO-2008099210-A2 PIPERAZINE DERIVATIVES FOR TREATMENT OF AD AND RELATED CONDITIONS MERCK & CO., INC. (US) 2008-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204230-A1 PIPERAZINE DERIVATIVES FOR TREATMENT OF AD AND RELATED CONDITIONS PSEN1, PSEN2, APP GFER 3132/4885CYP2C19 2877/4885NPSR1 449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.